Study Enrollment

Your details will not be published or shared.

Clinical Trial

A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer

This is a study involving advanced solid tumors and cervical cancer. The study is being done to test AGEN2034 as an immune therapy that targets a patient's immune cells to block a receptor called PD-1. This therapy is designed to improve the ability of the patient's immune system to fight cancer.

Eligibility Criteria

  • Safety Cohort (Dose Escalation) Patients must be at least 18 years of age or older. Must have proven metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed. Evidence of objective disease. A measurable lesion is not necessary. Efficacy Expansion Cohort (Second-Line Cervical Cancer) Subjects must have recurrent, unresectable, or metastatic cervical cancer and have relapsed after a platinum-containing doublet adminstered for treatment of advanced disease. Ineligible tumors are: minimal deviation/adenoma malignum, gastric type adenocarcinoma, clear cell carcinoma and mesonephric carcinoma.

Contact Information

    Kelly Jenkins, RN

    (706) 721-7407